1172 - Long acting octreotide in pts with disseminated neuroendocrine tumors

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Neuroendocrine Cancers
Supportive Care
Presenter Alla Markovich
Authors A. Markovich, G. Emelianova, V. Gorbounova, V. Bruzgin, N. Orel
  • Dept. Of Chemotherapy, N.N.Blokhin Russian Cancer Research Center of RAMN, 115478 - Moscow/RU

Abstract

Objectives

To evaluate the effectiveness of long acting octreotide at the doses 30 - 40 mg per month in heavily pretreated pts (pts) with disseminated neuroendocrine tumors (NET).

Patients and methods

31 pts with disseminated NET, progressing on different treatment regimens. We used long acting octreotide: Sandostatin-LAR, Octreotide-Depo, Octreotide-LONG. Origin of the tumor were: pancreas (3 pts, 9.7%), intestines (15 pts, 48.4%), lung (1 pt, 3.2%), kidney (1 pt, 3.2%), or unknown (11 pts, 35.5%).Tumor grades were as follows: G1 - 8 (25.8%), G2 - 14 (45.2%), G3 -1 (3.2%), unknown - 8 (25.8%). Isolated liver metastases were found in 15 pts (48.4%). 12 pts (38.7%) had liver metastases in combination with other sites of involvement. Carcinoid syndrome along with high levels of serum chromogranin A, serotonin and 5-OIAA were present in 29 pts (93.5%). Initially, 29 pts received long acting octreotide 20 mg for an average of 20 months (range, 3-60). The reasons for dose escalation were disease progression in 19 pts (61.3%), increase in markers and lack of control of carcinoid syndrome in 12 pts (38.7%). In 18 pts (58%) the dose was 30 mg, in 13 pts (42%) — 40 mg. 14 pts received long acting octreotide only (45.1%), 6 pts (19.4%) — in combination with α-interferon, 11 pts (35.5%) - in combination with chemotherapy.

Results

In 14 pts receiving long acting octreotide only, objective responses were not observed; 11pts (78.6%) had stable disease (SD), 3 pts (21.4 %) progressed. Median time to progression was not reached. The pts were followed for a median of 13.5 months. 5 pts (35.7%) are still receiving the treatment after 20 months. In the total group PR (partial response) was observed in 1 pts (3.2%), receiving octreotide with chemotherapy, SD — in 25 pts (80.7%), PD — in 5 pts (16.1%). Control of tumor growth was achieved in 83.9% of cases, these pts got a biochemical response and obtained symptom relief. In the total group the median time to progression was 18 months. Median survival was not reached. Tolerability of long-acting octreotide in a dose of 30-40 mg was satisfactory for all pts.

Conclusion

long acting octreotide at doses of 30-40 mg, alone or in combination with other types of drug treatment, controls the growth of disseminated tumors in most pts progressing on a lower dose, and has a good tolerability.

Disclosure

All authors have declared no conflicts of interest.